Rapid Rx Quiz: COVID Treatments

Mary L. Windle, PharmD

Disclosures

March 01, 2022

In a double-blind study, nirmatrelvir-ritonavir treatment (Paxlovid) reduced risk for hospitalization and death risk by 89% vs placebo among high-risk adults infected with COVID-19 who were not hospitalized when administered with 3 days of symptom onset. No deaths were reported among patients who received ritonavir in the overall study population through day 28 compared with the placebo group, in which 10 deaths occurred.

Learn more about nirmatrelvir-ritonavir.

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.

processing....